404009-40-1 Usage
Uses
Used in Pharmaceutical Industry:
IC86621 is used as an inhibitor for DNA-PK and PI 3-Kinase catalytic subunit p110β to enhance DSB-induced antitumor activity in cancer treatment. Its selective inhibition of these targets allows for potential use in developing targeted therapies for cancer patients.
Used in Research and Development:
IC86621 is used as a research tool to study the role of DNA-PK and PI 3-Kinase in cellular processes, particularly in the context of DNA repair and cancer progression. Its potent and selective inhibition properties make it a valuable compound for investigating the underlying mechanisms of these pathways and identifying potential therapeutic targets.
Used in Drug Development:
IC86621 is used as a lead compound in the development of new drugs targeting DNA-PK and PI 3-Kinase, with the aim of improving the efficacy and selectivity of cancer treatments. Its ATP-competitive nature and lack of cytotoxic effects at certain concentrations make it a promising candidate for further optimization and development into a therapeutic agent.
Used in Drug Delivery Systems:
IC86621 can be employed in the development of novel drug delivery systems to improve its bioavailability, delivery, and therapeutic outcomes in cancer treatment. By incorporating IC86621 into various organic and metallic nanoparticles or other advanced delivery platforms, its potential as an antitumor agent can be further enhanced, potentially leading to more effective cancer treatments.
Biochem/physiol Actions
Cell permeable: yes
Check Digit Verification of cas no
The CAS Registry Mumber 404009-40-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,0,4,0,0 and 9 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 404009-40:
(8*4)+(7*0)+(6*4)+(5*0)+(4*0)+(3*9)+(2*4)+(1*0)=91
91 % 10 = 1
So 404009-40-1 is a valid CAS Registry Number.
InChI:InChI=1/C12H15NO3/c1-9(14)11-3-2-10(8-12(11)15)13-4-6-16-7-5-13/h2-3,8,15H,4-7H2,1H3
404009-40-1Relevant academic research and scientific papers
Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold
Knight, Zachary A.,Chiang, Gary G.,Alaimo, Peter J.,Kenski, Denise M.,Ho, Caroline B.,Coan, Kristin,Abraham, Robert T.,Shokat, Kevan M.
, p. 4749 - 4759 (2007/10/03)
Phosphoinositide 3-kinases (PI3-Ks) are an ubiquitous class of signaling enzymes that regulate diverse cellular processes including growth, differentiation, and motility. Physiological roles of PI3-Ks have traditionally been assigned using two pharmacological inhibitors, LY294002 and wortmannin. Although these compounds are broadly specific for the PI3-K family, they show little selectivity among family members, and the development of isoform-specific inhibitors of these enzymes has been long anticipated. Herein, we prepare compounds from two classes of arylmorpholine PI3-K inhibitors and characterize their specificity against a comprehensive panel of targets within the PI3-K family. We identify multiplex inhibitors that potently inhibit distinct subsets of PI3-K isoforms, including the first selective inhibitor of p110β/p110δ (IC50 p110β = 0.13 μM, p110δ = 0.63 μM). We also identify trends that suggest certain PI3-K isoforms may be more sensitive to potent inhibition by arylmorpholines, thereby guiding future drug design based on this pharmacophore.
